Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center
Cancer Medicine · 2024
DOI: 10.1002/cam4.7292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Ant Uzay und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Department of Hematology and Stem Cell Transplantation, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Busulfan, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Type of conditioning regimen impacts the outcome of patients who undergo allogeneic HSCT since graft versus host disease (GVHD), infections, regimen related toxicities (RRT) are important causes of post‐transplant mortality. Despite the RRT profile of busulfan, it is frequently used worldwide. Treosulfan has advantages in terms of dose of administration, lower incidence of sinusoidal obstruction syndrome and lower neurotoxicity. We retrospectively investigated outcomes of patients who underwent allogeneic HSCT with treosulfan or busulfan based conditioning regimens in our institution.
Methods
Treosulfan was administered to 94 patients while 85 patients received busulfan. Our outcomes were RRT, chronic and acute GVHD, relapse related mortality (RRM), non‐relapse mortality, and fungal infection. The clinical follow up data, regarding the primary and secondary endpoints of our study, of the patients who received treosulfan or busulfan based conditioning regimens were statistically analyzed.
Results
The median follow‐up was 14 months for the treosulfan group while it was 11 months for the busulfan group ( p = 0.16). RRT was 11.7% and 7.1% for treosulfan and busulfan respectively. The incidence of extensive chronic GVHD was less frequent in the treosulfan group compared to the busulfan group (15.7% vs. 32.1%) ( p < 0.001). The incidence of acute GVHD (Grade 3 or higher) was 32.2% in the treosulfan group while it was 31.6% in the busulfan group. The RRM was 17% in the treosulfan group while it was 34% in the busulfan group. The non‐relapse mortality was 35.5% and 29.4% in the treosulfan group and in the busulfan group respectively ( p = 0.962).
Conclusion
Treosulfan, with a lower RRM, lower chronic GVHD incidence and with a similar RRT profile appears to be a safe alternative to busulfan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Department of Hematology and Stem Cell Transplantation, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey.
- School of Medicine, Department of Internal Medicine, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey.
- School of Medicine, Clinical Nursing, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Turkey.
ORCID-Profile: Ant Uzay, Yasemin Gündoğdu, Barış Koşan, Tuğba Yetiş, S Sami Kartı
Zitieren
APA
Uzay, A., Gündoğdu, Y., Koşan, B., Yetiş, T., & Kartı, S. S. (2024). Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center. Cancer Medicine. https://doi.org/10.1002/cam4.7292
Vancouver
Uzay A, Gündoğdu Y, Koşan B, Yetiş T, Kartı SS. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center. Cancer Medicine. 2024. doi:10.1002/cam4.7292
BibTeX
@article{Uzay2024,
author = {Uzay, Ant and Gündoğdu, Yasemin and Koşan, Barış and Yetiş, Tuğba and Kartı, S Sami},
title = {Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7292}
}
EUVIMED